In a 6-month study in patients with moderate-to-severe COPD (post-bronchodilator mean forced expiratory volume in 1 second [FEV1] 54% predicted [8]), the PDE4 inhibitor roflumilast improved lung function and reduced exacerbations [9]. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.